SPRB
Spruce BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that TA-ERT has a clearer FDA path after the Type B meetings, the Q4 2026 BLA target is achieved, and investors begin underwriting first-mover value in MPS IIIB plus access to milestone-linked debt capital.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.2.
What can break
Additional Avenue debt tranches are milestone-gated rather than fully committed upfront.
Momentum
7
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $120.00 · Bear $34.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $151.00
Why
Momentum7 · Δ7d -2.4
Value41 · Δ7d -0.1
Sentiment100 · Δ7d +5.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
7
26% active weight
Current posture
7d trendFlat
Δ7d
-2.4
Δ21d
-5.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+22.1
Why this grade
Composite grade C. Momentum 7.0 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$119.83M
Beta
3.59
Shares Out
2.75M
P/E (TTM) · Derived
-0.9
P/S (TTM)
126.11
P/FCF (TTM) · Derived
-1.23
Rev YoY
-100.0%
EPS YoY
-62.7%
Gross Margin
+96.4%
Op Margin
-7100.0%
Net Debt
-$48.17M
Current Ratio
4.67
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology